RNAZ - Transcode Therapeutics, Inc.
0.3552
-0.007 -1.943%
Share volume: 1,436,512
Last Updated: 05-07-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.13%
PREVIOUS CLOSE
CHG
CHG%
$0.36
-0.01
-0.02%
View ratios
| Fiscal Date | 12-31-2023 | 06-30-2024 | 09-30-2024 | |
|---|---|---|---|---|
| Fiscal Quarter | Q4 2023 | Q2 2024 | Q3 2024 | |
| Report Date | 11-14-2024 | 08-14-2024 | 11-14-2024 | |
| Total revenue | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | |
| nan% | ||||
| Operating expenses | 6.119 M | 5.114 M | 2.165 M | |
| Selling general and admin | 1.172 M | 2.032 M | 938.026 K | |
| Research and development | 4.947 M | 3.082 M | 1.227 M | |
| Total expenses | 6.119 M | 5.114 M | 2.165 M | |
| -16.42% | -57.66% | |||
| Operating income | -6.119 M | -5.114 M | -2.165 M | |
| Ebit | -6.036 M | -5.187 M | -2.311 M | |
| Pretax income | -6.061 M | -5.191 M | -2.321 M | |
| -14.35% | -55.28% | |||
| Income tax | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | |
| Net income | -6.061 M | -5.191 M | -2.321 M | |
| 14.35% | 55.28% |
